2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

653. Multiple Myeloma: Clinical and Epidemiological: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Omics Technologies, Pathology, Serologic Tests, Treatment Considerations, Combination Therapy, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Radiation Therapy, Workforce, Adverse Events, Artificial Intelligence (AI), Deep Learning, Biological Processes, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Bleeding and Clotting, Thromboembolism, Immunology, Immunodeficiency, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

2212 The prognostic significance of 17p deletion in newly diagnosed multiple myeloma patients by FISH and SNP-array detection

wenli Jin, Chengcheng Fu, MD,PhD2, Jinlan Pan3, Honghang Zhou4, Hongying You5, Zhi Yan6, Shuang Yan7, Weiqin Yao8, Depei Wu Sr, MD9
1 First Affiliated Hospital of Soochow University, Suzhou, China
2 First Affiliated Hospital of Soochow University, Suzhou, China, National Clinical Research Center for Hematologic Diseases, Suzhou, China
3 First Affiliated Hospital of Soochow University, Suzhou, China, Jiangsu Institute of Hematology, Suzhou, China
4 First Affiliated Hospital of Soochow University, Suzhou, China
5 First Affiliated Hospital of Soochow University, Suzhou, China
6 First Affiliated Hospital of Soochow University, Suzhou, China
7 First Affiliated Hospital of Soochow University, Suzhou, China
8 First Affiliated Hospital of Soochow University, Suzhou, China
9 First Affiliated Hospital of Soochow University, Suzhou, China, Jiangsu Institute of Hematology,, Suzhou, China, Jiangsu Key Laboratory of Hematologic Diseases, Suzhou, China, National Clinical Research Center for Hematologic Diseases, Suzhoou, China

Objective:

Deletion of 17p is a well-recognized high-risk prognostic biomarker for multiple myeloma, accounting for approximately 10% of all cases of NDMM. In 2025, the International Myeloma Society/International Myeloma Working Group (IMS/IMWG) defined high-risk MM as a del(17p) clonal proportion of ≥20% detected by FISH, while microarray technology can further identify 17p deletions at the level of copy number abnormalities. This study combined these two detection technologies to investigate the effect of the clonal proportion of 17p deletion on the prognosis of MM.

Methods:

A total of 564 patients with newly diagnosed multiple myeloma diagnosed at the First Affiliated Hospital of Soochow University between August 1, 2018, and December 31, 2024, were enrolled in this study. FISH and SNP-array detection results after CD138 sorting of all patients’ bone marrow samples were obtained from the Jiangsu Province Hematology Samples BioBank of China.

Results:

The median age of the patients was 60 years (range: 29-81 years), and 54.6% of the patients were male. 91.5% of the patients were at DS stage III. 72.8% of the patients received VRD induction therapy, 19.5% received Dara-based four-drug combination regimens, and 2.8% received DRD regimens, 2.6% received other three-drug regimens. ASCT was performed in 59.6% of the patients.

Del(17p) patients, who accounted for 15% of the total cohort, presented more frequent clinical aggressiveness: 35% were at R-ISS stage III, 19% developed thrombocytopenia and elevated LDH, 22.6% developed hypercalcemia, and light-chain M protein accounted for 34.5% (all p<0.05) compared with patients without 17p-. Patients with del(17p) were more likely to have concurrent del(13q14) (76.2%, P<0.001) and del(1p32) (31.0%, P<0.001). Complex karyotype was observed in 89.3% of del(17p) patients (P<0.001), and the incidence of hypodiploid karyotype was high (48.8%). The proportion of patients receiving different induction regimens and ASCT was consistent between the two groups, but 72.4% of del(17p) patients received VR maintenance therapy.

Regardless of whether del(17p) occurs alone or in combination with other high-risk cytogenetic abnormalities, only a 17p deletion proportion of ≥20% detected by FISH or ≥12% detected by microarray has clinical significance for poor prognosis. Compared with patients without del(17p), isolated del(17p) was associated with inferior outcomes with a median PFS of 49m vs 81m, P=0.005. However, the 36-month OS rates were similar between two groups (95.5% vs 94.2%, P=0.743). Patients with double- or triple-hit cytogenetic abnormalities involving del(17p) had significantly poorer outcomes (median PFS 31m vs 54m, P=0.016, 36-month OS 68.4% vs87.8%, P<0.001). There was no statistically significant difference in PFS and OS between the <20% 17p- group and the patients without 17p-.

Compared with del(17p) in the subclone, del(17p) in the main clone had particularly worsen outcomes (median PFS:23m VS not reached, P=0.006; 36-month OS: 60.1% vs 87.6%, P=0.024). In contrast, no difference in prognosis was seen between patients with whole arm 17p deletion and those with partial 17p deletion.

Conclusion:

Combined detection of FISH and microarray after CD138 sorting samples can improve the detection rate of 17p deletion in patients with multiple myeloma. Del(17p) was linked to a poor prognosis only when the clonal fraction was more than 20% by FISH or more than 12% by SNP-array analysis. Notably, regardless of the clonal size, del(17p) located in the major clone may have the greatest impact on survival.

wenli Jin: No relevant conflicts of interest to declare.